目的　评价国产头孢哌酮 /舒巴坦钠治疗老年下呼吸道细菌性感染的临床疗效。方法　中、重度感染患者 6 0例随机分为观察组和对照组 ,各 30例。观察组应用国产头孢哌酮 /舒巴坦钠治疗 ,对照组使用头孢哌酮钠治疗。结果观察组和对照组临床有效率分别为 93.3%、90 .0 % ;细菌转阴率 92 .6 %、88.5 % ;产酶菌转阴率 89.5 %、82 .4 % ;细菌清除率 85 .2 %、80 .8% ;细菌敏感率 94 .3%、90 .6 % ;不良反应发生率 6 .6 7%、3.33% (P >0 .0 5 )。两组效价比分别为 (0 .39± 0 .2 9)与 (0 .19± 0 .11) (P <0 .0 5 )。结论　国产头孢哌酮 /舒巴坦钠效价比较高 ,临床试验结果满意 ,适于治疗中、重度老年下呼吸道细菌性感染 ,并有利于降低整体医疗费用成本。 Objective To evaluate the clinical efficacy of domestic cefoperazone / sulbactam sodium in the treatment of lower respiratory tract bacterial infections in the elderly. Methods, 60 cases of severe infections were randomly divided into observation group and control group, 30 cases in each. The observation group was treated with domestic cefoperazone / sulbactam sodium and the control group was treated with cefoperazone sodium. Results The clinical effective rates of the observation group and the control group were 93.3% and 90.0% respectively. The negative rates of bacteria were 92.6% and 88.5%, respectively. The negative rates of producing bacteria were 89.5% and 82.4%, respectively. 2% and 80.8% respectively. The sensitivity rate of bacteria was 94.3% and 90.6% respectively. The incidence of adverse reactions was 6.76% and 3.33%, respectively (P> 0.05). The titer of the two groups were (0.39 ± 0.29) and (0.19 ± 0.11), respectively (P <0.05). Conclusion Domestic cefoperazone / sulbactam sodium has high titer and satisfactory results in clinical trials. It is suitable for the treatment of bacterial infections of lower respiratory tract in middle-aged and severe elderly patients, and is beneficial to reduce the overall medical cost.